1-6 of 6
John F Seymour, MD, PhD
Close
Sort by
Journal Articles

International Phase III Study of Chlorambucil Versus Fludarabine As Initial Therapy for Waldenstrom's Macroglobulinemia and Related Disorders: Results in 414 Patients on Behalf of FCG CLL/ WM, GOELAMS, GELA, NCRI, ALLG

Veronique Leblond, Julie Lejeune, Olivier Tournilhac, MD, PhD, Pierre Morel, marie Sarah Dilhuydy, Caroline Dartigeas, Dr., Marion Malphette, Bruno Royer, John F. Seymour, MD, PhD, Sylvie Chevret, Steve Johnson, Roger G Owen, MD
Journal: Blood
Blood (2011) 118 (21): 776.
https://doi.org/10.1182/blood.V118.21.776.776
Published: 2011
Journal Articles

Symptoms and Toxicity of Rituximab Maintenance (R-M) Versus Observation (OBS) Following Rituximab Plus Chemotherapy in Patients with Follicular Lymphoma,

Xiaolei Zhou, Jianmin Wang, Jessica Zhang, Catherine Copley-Merriman, Yasuhiro Torigoe, Carolina Reyes, PhD, John F. Seymour, MD, PhD, Armando Lopez-Guillermo, MD, Fritz C. Offner, MD, PhD, Marek Trneny, Gilles Andre Salles
Journal: Blood
Blood (2011) 118 (21): 3661.
https://doi.org/10.1182/blood.V118.21.3661.3661
Published: 2011
Journal Articles

Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL,

Maher K Gandhi, PhD, FRACP, FRCPath, FRCP, Mark S. Hertzberg, MD, PhD, Erica Han, John F. Seymour, MD, PhD, Rodney Hicks, MB BS, MD, FRACP, Devinder S Gill, MD, Colm Keane, MB BCh BAO MSc MRCPI FRCPath, Pauline Crooks, Kristen Radford, PhD, Frank Vari, Phd
Journal: Blood
Blood (2011) 118 (21): 3673.
https://doi.org/10.1182/blood.V118.21.3673.3673
Published: 2011
Journal Articles

The Addition of Rituximab to Fludarabine and Cyclophosphamide (FC) Improves Overall Survival in Newly Diagnosed Mantle Cell Lymphoma (MCL): Results of the Randomised UK National Cancer Research Institute (NCRI) Trial

Simon Rule, MD, Paul Smith, Peter W Johnson, MD, Simon Bolam, MD, George A Follows, Jo Gambell, Peter Hillmen, MBChB, PhD, Andrew Jack, PhD, MB, Stephen A. N. Johnson, MBBS, FRCP, FRCPath, Amy Kirkwood, Anton Kruger, MBChB, FRCP, FRCPath, John F. Seymour, MD, PhD, Milena Toncheva, Jan Walewski, MD, PhD, David C Linch, MD FMedSci
Journal: Blood
Blood (2011) 118 (21): 440.
https://doi.org/10.1182/blood.V118.21.440.440
Published: 2011
Journal Articles

Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis

Rami S. Komrokji, MD, Martha Wadleigh, MD, John F. Seymour, MD, PhD, Andrew W. Roberts, MD, PhD, Luen Bik To, Huan J. Zhu, MD, PhD, Ruben A. Mesa, MD
Journal: Blood
Blood (2011) 118 (21): 282.
https://doi.org/10.1182/blood.V118.21.282.282
Published: 2011
Journal Articles

First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group.

Michael Hallek, MD, Guenter Fingerle-Rowson, MD, PhD, Anna-Maria Fink, MD, Raymonde Busch, Jiri Mayer, MD, Manfred Hensel, MD, Georg Hopfinger, MD, Georg Hess, MD, Ulrich von Gruenhagen, MD, Manuela A. Bergmann, MD, John Catalano, MD, Pier Luigi Zinzano, MD, Federico Caligaris Cappio, MD, John F Seymour, MD, PhD, Alain Berrebi, MD, Ulrich Jaeger, MD, Bruno Cazin, MD, Marek Trneny, MD, Anne Westermann, Clemens-Martin Wendtner, MD, Barbara F. Eichhorst, MD, Peter Staib, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Myriam Mendila, MD, Michael Kneba, MD, PhD, Hartmut Doehner, MD, Stephan Stilgenbauer, MD, Kirsten Fischer, MD
Journal: Blood
Blood (2009) 114 (22): 535.
https://doi.org/10.1182/blood.V114.22.535.535
Published: 2009